AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

Clinical trial NCT07194382 · RECRUITING

Trial details

NCT number: NCT07194382
Sponsor: Avalyn Pharma Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Idiopathic Pulmonary Fibrosis (IPF)

Start date: 2026-03-10
Primary completion: 2026-12-01
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.